Translational Neural Devices (UG3/UH3 - Clinical Trial Optional) | RFA NS 21 021

FAQs: NIH Translational Neural Devices (UG3/UH3 - Clinical Trial Optional) (RFA-NS-21-021)

What is this funding opportunity about?

This NIH opportunity supports translational work to move promising therapeutic or diagnostic devices for nervous system and neuromuscular disorders from late-stage development into practical, testable products. The focus is on activities that push a device toward real-world use, rather than early discovery research.

What kinds of devices are in scope?

The FOA targets therapeutic or diagnostic devices intended for nervous system and neuromuscular disorders. The emphasis is on neural and neuromuscular device development at a stage where engineering refinement, testing, and regulatory preparation are the main remaining hurdles to readiness for broader clinical validation or commercialization pathways.

Is this opportunity meant for early-stage discovery research?

No. The FOA emphasizes translational development, not early discovery. Projects are expected to center on concrete development outcomes such as prototype refinement, verification/validation testing, and regulatory readiness steps.

What development activities can be supported?

The program can support common late-stage bottleneck activities, including building and refining a clinical prototype; performing non-clinical safety and efficacy testing; completing design verification and validation; and taking regulatory and ethics steps needed to begin human research. When justified, it can also support a small clinical study to answer focused questions tied to device function or final design decisions.

What examples of non-clinical testing are mentioned?

Examples described include benchtop verification, animal studies when appropriate, biocompatibility testing, electrical safety testing, software testing, and other performance assessments intended to reduce uncertainty about whether the device works as intended and is ready for human use or the next development phase.

What does "design verification and validation" mean in the context of this FOA?

As described, design verification and validation activities are those that demonstrate the device meets specifications and user needs. In practice, this is the type of testing and documentation used to show the device performs as intended and supports real-world use cases.

Does this FOA allow clinical trials?

Clinical studies are optional. The FOA allows a subsequent small clinical study after appropriate regulatory and ethics steps are completed, but only when a clinical component is tightly justified and cannot reasonably be replaced by additional non-clinical testing.

What kinds of clinical studies are appropriate under this FOA?

The clinical work, if included, is intended to be small and focused. Examples of appropriate clinical questions include device function, usability, feasibility, real-world signal quality, stimulation tolerability, workflow integration, and other human factors that directly impact final design choices.

What kinds of clinical studies are not the focus of this program?

This FOA is not meant for large pivotal trials and is not meant to replace thorough bench or animal work. The clinical portion is framed as a limited human evaluation used only when needed to answer questions that cannot realistically be resolved non-clinically.

What regulatory and ethics steps can be supported?

The announcement explicitly includes support for steps needed to begin human research, such as preparing for and obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or securing Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study.

When would an IDE or IRB process come into play for a project?

These steps become relevant when a project is preparing to conduct human research. The FOA highlights IDE preparation/approval for Significant Risk studies and IRB approval pathways for Non-Significant Risk studies as examples of the regulatory and ethics activities that may be necessary before a small clinical study can begin.

What is the UG3/UH3 structure?

The FOA uses a UG3/UH3 structure. Based on the description provided, this is a milestone-driven approach intended to support a progression of work from late-stage development activities through readiness for (and potentially execution of) a small, focused clinical study when justified.

What does it mean that this is a cooperative agreement?

A cooperative agreement indicates a more hands-on partnership with NIH than a standard research grant. NIH program staff are described as working with awardees to negotiate and finalize the project plan before funding begins and monitoring progress over time.

What does "milestone-driven" mean for applicants and awardees?

Applicants are expected to propose clear, measurable technical and regulatory milestones. NIH staff will work with awardees to negotiate and finalize milestones, and continued support is typically tied to meeting the agreed-upon milestones. The intent is to keep projects focused on concrete development outcomes and reduce the risk of open-ended work that does not translate into a usable device.

How does NIH involvement affect project planning?

NIH program staff are described as partnering with awardees to negotiate and finalize the plan before funding begins, then monitoring progress against milestones. This suggests that the project plan is expected to be specific, measurable, and oriented toward deliverables that advance the device toward practical use.

What is the maximum award amount listed?

The listing includes an award ceiling of $1,000,000.

Is the number of expected awards known?

The expected number of awards is not specified in the provided details.

What is the closing date shown for this opportunity?

The original closing date shown is 2024-02-20.

When was this opportunity created?

The opportunity was created on 2021-04-28.

What is the funding instrument and funding type?

The funding instrument is a cooperative agreement, and the opportunity is categorized as discretionary funding.

What is the CFDA program number and area mentioned?

The opportunity is listed under CFDA 93.853, described as a health-related funding activity area.

Who is eligible to apply?

Eligibility is broad and includes many organization types. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized governments); public housing authorities and Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; and small businesses.

Are specific institution types (HSIs, HBCUs, tribal colleges, etc.) mentioned as eligible?

Yes. The FOA calls out additional eligible groups including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, and faith-based or community-based organizations, among others.

Are U.S. territories or non-U.S. (foreign) organizations eligible?

Yes. The eligibility language includes U.S. territories or possessions and non-U.S. entities (foreign organizations) as eligible.

Can federal agencies apply?

Yes. The FOA includes eligible federal agencies in the list of eligible applicants.

What is the overall purpose of the program in practical terms?

In practical terms, the program supports engineering, testing, and regulatory preparation (and limited human evaluation when truly needed) to reduce uncertainty about device performance and readiness. The intent is to position devices for larger clinical validation efforts or commercialization pathways rather than leaving them in an academic prototype stage.

How should applicants think about the clinical component if they include one?

The FOA frames clinical work as something that should be included only when it is tightly justified and when the information needed cannot realistically be obtained through additional non-clinical testing. It is positioned as a targeted step to inform final design choices or confirm key aspects of usability or function in humans.

What types of teams does NIH appear to be trying to attract?

The eligibility language and translational emphasis suggest NIH is trying to attract multidisciplinary teams across academia, industry, and community-centered or government-affiliated organizations that can deliver a clinical prototype, complete testing and regulatory steps, and, when justified, conduct a small human study.